We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

139 hedge funds and large institutions have $376M invested in Catalyst Pharmaceutical in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 57 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 16

21% more capital invested

Capital invested by funds: $312M → $376M (+$64.5M)

5% more funds holding

Funds holding: 133139 (+6)

1.84% less ownership

Funds ownership: 65.2%63.36% (-1.8%)

32% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 57

75% less call options, than puts

Call options by funds: $634K | Put options by funds: $2.57M

Holders
139
Holders Change
+6
Holders Change %
+4.51%
% of All Funds
2.42%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
39
Reduced
57
Closed
16
Calls
$634K
Puts
$2.57M
Net Calls
-$1.94M
Net Calls Change
-$2.5M
Name Holding Trade Value Shares
Change
Change in
Stake
Pacer Advisors
151
Pacer Advisors
Pennsylvania
-$47K -10,206 Closed
SPIA
152
Steward Partners Investment Advisory
New York
-$12K -2,600 Closed
SFS
153
Sowell Financial Services
Arkansas
-$8K -1,784 Closed
New York State Teachers Retirement System (NYSTRS)
154
New York State Teachers Retirement System (NYSTRS)
New York
-$5K -1,100 Closed
EP
155
Eudaimonia Partners
Tennessee
-$5K -1,000 Closed

CPRX Hedge Fund Activity: Q2 2021 in Review

139 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2021, worth a combined $376M — up 21% from $312M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CPRX positions and 16 closed out — a net gain of 7 holders — while 39 added to existing stakes and 57 trimmed.

The largest buyer was LSV Asset Management, adding an estimated $14.6M. The largest seller was State Street, cutting an estimated $15.1M.

  • 139 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2021, up from 133 in Q1 2021.
  • Funds reported $376M of Catalyst Pharmaceutical stock for Q2 2021, up 21% quarter-over-quarter.
  • 23 funds opened new Catalyst Pharmaceutical positions in Q2 2021 and 16 closed out, a net change of +7 holders.
  • The largest Catalyst Pharmaceutical buyer in Q2 2021 was LSV Asset Management, an estimated $14.6M added.
  • The largest Catalyst Pharmaceutical seller in Q2 2021 was State Street, an estimated $15.1M sold.

Based on aggregated 13F filings for Q2 2021.